ADVISORY, May 04, 2017 (GLOBE NEWSWIRE) --
What: Radius Health, Inc. (Nasdaq: RDUS ), a science-driven fully integrated biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine disease, will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Robert E. Ward, President & Chief Executive Officer, and Dr. Greg Williams, Chief Development Officer, will ring the Opening Bell.
Where: Nasdaq MarketSite – 4 Times Square – 43 rd & Broadway – Broadcast Studio
When: Friday, May 5, 2017 – 9:15 a.m. to 9:30 a.m. ET
Radius Health Media Contact: Lori Gorski 617-551-4096 lgorski@radiuspharm.com
Nasdaq MarketSite: Emily Pan (646) 441-5120 emily.pan@nasdaq.com
Feed Information: Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media: For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page: http://www.facebook.com/NASDAQ .
For photos from ceremonies and events, please visit our Instagram page: http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our YouTube page: http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter page: http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our Tumblr page: http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq Opening Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice.
About Radius Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product, TYMLOS (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture in April 2017. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in postmenopausal women with osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius' RAD140, a non-steroidal, selective androgen receptor modulator (SARM), is under investigation for potential use in hormone receptor positive breast cancer. For more information, please visit www.radiuspharm.com .
About Nasdaq Nasdaq (Nasdaq: NDAQ ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 89 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to 3,800 total listings with a market value of $11 trillion. To learn more, visit: http://business.nasdaq.com .
-NDAQA-
